RecruitingRecruiting
Quantitative Chest CT and Multi-Omics to Distinguish Asthma From COPD and Predict Treatment Response
NCT07602192 · Korea University Guro Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Prospective Multicenter Cohort to Discriminate Asthma Versus Chronic Obstructive Pulmonary Disease and Predict Treatment Response Using Quantitative Chest CT and Multi-Omics
About this study
This is a prospective, observational, multi-center cohort study designed to integrate quantitative chest CT imaging with multi-omics data to improve differentiation between asthma and chronic obstructive pulmonary disease (COPD) and to identify biomarkers associated with treatment response.
Eligible participants will include adults diagnosed with asthma or COPD who agree to participate in longitudinal clinical follow-up. At baseline and during follow-up, participants will undergo standard clinical assessments, including symptom questionnaires, pulmonary function testing, blood sampling, and chest CT imaging. Additional biological samples, such as sputum and microbiome specimens, may be collected when clinically feasible.
Quantitative CT metrics (e.g., low attenuation area percentage, parametric response mapping features, airway wall measurements, and mucus plug scores) will be extracted from imaging data. These imaging biomarkers will be integrated with clinical variables, laboratory parameters (including inflammatory markers and immunoglobulin profiles), and microbiome data.
The primary objectives are: (1) to identify imaging and biological signatures that distinguish asthma from COPD, and (2) to determine whether these signatures can predict response to standard clinical treatments. No investigational drugs or medical devices are involved, and all procedures reflect routine clinical care.
Data will be analyzed using advanced statistical and computational methods to explore associations between imaging, biological markers, and clinical outcomes. Results are expected to enhance understanding of disease mechanisms and support the development of personalized treatment strategies for chronic airway diseases.
Eligibility criteria
Inclusion Criteria:
* Age ≥19 years
* COPD group: post-bronchodilator FEV1/FVC \< 0.70
* Asthma group: clinically confirmed diagnosis of asthma by a physician
* Able to provide voluntary written informed consent
Exclusion Criteria:
* Acute exacerbation or active lower respiratory tract infection (e.g., pneumonia) within the past 4 weeks
* Pregnancy or breastfeeding
* Inability to undergo chest CT (e.g., poor cooperation or severe medical condition)
* Refusal to consent to study procedures
Study design
Enrollment target: 200 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-12-22
Estimated completion: 2027-12-22
Last updated: 2026-07-07
Primary outcomes
- • Imaging and multi-omic signatures that differentiate asthma from COPD and predict treatment response (From baseline to last follow-up visit (anticipated up to 12 months after enrollment))
Sponsor
Korea University Guro Hospital · other
With: The Korean Academy of Tuberculosis and Respiratory Diseases, Seoul National University Boramae Hospital
Contacts & investigators
ContactSang Hyuk Kim, MD · contact · gost702@korea.ac.kr · +82-2-2626-1659
ContactClinical Research Office Korea University Guro Hospital · contact · kumc.guro.rst@kumc.or.kr · +82-2-2626-1659
InvestigatorSang Hyuk Kim, MD · principal_investigator, Korea University Guro Hospital
All locations (2)
SMG-SNU Boramae Medical CenterRecruiting
Seoul, Dongjak-gu, South Korea
Korea University Guro HospitalRecruiting
Seoul, Guro-gu, South Korea